Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_
_x000D_
#What Are the Latest Market Insights for the Gene Therapy For Inherited Genetic Disorders Industry?#_x000D_
In recent times, the market for gene therapy for inherited genetic disorders has shown significant growth. The market forecast suggests a growth from $3.39 billion in 2024 to $4.05 billion in 2025, showing a compound annual growth rate (CAGR) of 19.4%. The historic growth can be linked to factors such as enhanced government strategies and backing for gene therapy, improved gene delivery systems becoming more accessible, rising patient need for effective curative treatments, an increase in clinical trials focusing on inherited disorders, and an uptick in comprehension of gene therapy advantages amongst healthcare professionals._x000D_
_x000D_
The market size for gene therapy for inherited genetic disorders is projected to experience accelerated expansion in the coming years. It is set to increase to $8.15 billion in 2029, with a compound annual growth rate (CAGR) of 19.1%. The surge during the forecast period can be associated with the rising prevalence of inherited genetic disorders, enhancements in funding and investments for gene therapy research and development, escalating awareness and diagnosis rates of rare genetic conditions, increasing approvals of new gene therapy products by regulatory bodies, and the expanding use of personalized medicine approaches. Significant trends expected in the forecast period encompass the inclusion of advanced delivery systems for targeted gene therapy, progression in viral and non-viral vector technology, advancements in next-generation sequencing facilitating precise diagnosis, technological enhancements in production and scalability of gene therapies, and use of artificial intelligence to perfect gene therapy design._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=27293&type=smp_x000D_
_x000D_
#What Forces Are Driving The Growth Of The Gene Therapy For Inherited Genetic Disorders Industry?#_x000D_
The growing preference for personalized medicine is anticipated to accelerate the expansion of the market for gene therapy for inherited genetic disorders. Personalized medicine represents the adjustment of medical care to match the genetic profile and individual features of a patient for enhanced treatment. Progress in genetic technology has enhanced the prominence of personalized medicine by making it simpler and more cost-effective to customize treatment to a person’s specific genetic composition. Personalized medicine improves gene therapy by adjusting treatments to fit each patient’s specific genetic profile, guaranteeing accurate gene targeting and delivery while magnifying effectiveness and minimizing side-effects. For example, the Personalized Medicine Coalition, a non-profit organization based in the US, reported in February 2024 that in 2023, the United States Food and Drug Administration (FDA) authorized 16 new personalized treatments for rare disease patients, which was a rise from six in 2022. The freshly approved personalized treatments for 2023 also incorporated seven cancer drugs and three for other diseases and health issues. Hence, the surging interest in personalized medicine is fueling the expansion of the gene therapy market for inherited genetic disorders._x000D_
_x000D_
#What Is The Overview Of Market Segmentation In The Gene Therapy For Inherited Genetic Disorders Industry?#_x000D_
The gene therapy for inherited genetic disorders market covered in this report is segmented_x000D_
_x000D_
1) By Type: Viral Vector-Based Therapies, Gene Editing Techniques, Ribonucleic Acid-Based Therapies, Ex Vivo Gene Therapy_x000D_
2) By Application: Inherited Metabolic Disorders, Neurological Disorders, Cardiovascular Disorders, Musculoskeletal Disorders, Ophthalmic Disorders_x000D_
3) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Viral Vector-Based Therapies: Adenovirus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentivirus Vectors_x000D_
2) By Gene Editing Techniques: Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Meganucleases_x000D_
3) By Ribonucleic Acid-Based Therapies: Small Interfering Ribonucleic Acid, Antisense Oligonucleotides (ASOs), Messenger Ribonucleic Acid (mRNA) Therapies_x000D_
4) By Ex Vivo Gene Therapy: Hematopoietic Stem Cell Gene Therapy, Mesenchymal Stem Cell Gene Therapy, Induced Pluripotent Stem Cell (iPSC) Therapy_x000D_
_x000D_
#What Future Market Trends Are Projected For The Gene Therapy For Inherited Genetic Disorders Industry?#_x000D_
Significant enterprises in the inherited genetic disorders gene therapy market are prioritizing the development of forward-thinking solutions, such as gene therapy foundations, to deliver precise, reliable and efficient treatments that tackle the fundamental causes of genetic illnesses. A gene therapy foundation is a biotech or pharmaceutical firm that excels in researching, crafting, and marketing gene therapy treatments intended to rectify or alter faulty genes which cause inherited genetic disorders. For instance, Replay, an American company that specializes in genome writing, unveiled Telaria, an extensive DNA HSV gene therapy company, in November 2022. This is the second product company that capitalizes on its high payload capacity herpes simplex virus (HSV) delivery vector, synHSV, and its primary implication is recessive dystrophic epidermolysis bullosa (RDEB), an intense genetic skin disorder. The company was initiated by eminent HSV scientists and experts in genetic skin diseases, with the intention to generate revolutionary gene therapies for these uncommon skin diseases. This introduction comes after Replay’s initial gene therapy company, Eudora, which targets diseases of the retina. Replay’s innovative setup segregates technology advancement from therapeutic development across unique product companies that concentrate on particular disease fields._x000D_
_x000D_
#Who Are The Primary Players Operating Across The Global Gene Therapy For Inherited Genetic Disorders Market?#_x000D_
Major companies operating in the gene therapy for inherited genetic disorders market are Sanofi S.A., Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech, Biomarin Pharmaceutical Inc, Sarepta Therapeutics Inc., Krystal Biotech Inc., Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., Passage Bio Inc., Voyager Therapeutics Inc., Generation Bio Co., Avrobio Inc, Editas Medicine Inc., MeiraGTx Holdings Plc, uniQure N.V., Intellia Therapeutics Inc., Bluebird Bio Inc, 4D Molecular Therapeutics Inc., CRISPR Therapeutics AG. _x000D_
_x000D_
#Get The Full Report Here:#_x000D_
_x000D_
#Which Region Offers The Most Growth Potential For The Gene Therapy For Inherited Genetic Disorders Market Through 2029?#_x000D_
North America was the largest region in the gene therapy for inherited genetic disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for inherited genetic disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=27293&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model